Tiagabine-induced absence status in idiopathic generalized epilepsy

Seizure

Volumn 8, Issue 5, 1999, Pages 314-317

  Knake, S ^a   Hamer, H M ^a   Schomburg, U ^a   Oertel, W H ^a   Rosenow, F ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Absence status; Generalized epilepsy; Seizure induction; Status epilepticus; Tiagabine

Indexed keywords

ANTICONVULSIVE AGENT; LORAZEPAM; TIAGABINE; VALPROIC ACID;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; FEMALE; GENERALIZED EPILEPSY; HUMAN; PRIORITY JOURNAL; REMISSION;

EID: 0033180239     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1053/seiz.1999.0303     Document Type: Article

References (26)

1. Gastaut H. Classification of status epilepticus. Status epilepticus. Mechanisms of brain damage and treatment. Advances in Neurology. 34:1983;15-35.
2. Porter R. J., Penry J. K. Petit mal status. Advances in Neurology. 34:1983;61-67.
3. Rothner A. D., Morris H. H. Generalized status epilepticus. Lüders H., Lesser R. P. Epilepsy. Electroclinical Syndromes. 1987;207-222 Springer-Verlag, Berlin, Heidelberg.
4. Fischer R. Newer antiepileptic drugs. Wyllie E. The Treatment of Epilepsy. Principles and Practice. 1993;923-925 Williams and Wilkins, Baltimore.
5. Fink-Jensen A., Suzdak P. D., Swedbweg M. D. et al. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. European Journal of Pharmacology. 220:1992;197-201.
6. Walton N. Y., Gunawan S., Treiman D. Treatment of experimental status epilepticus with the GABA uptake inhibitor, tiagabine. Epilepsy Research. 19:1994;237-244.
7. Chadwick D., Richens A., Duncan J. et al. Tiagabine HCl: safety and efficacy as adjunctive treatment for complex partial seizures. Epilepsia. 32:1991;20.
8. Rowan J., Uthman B., Ahman P. et al. Safety and efficacy of three dose levels of tiagabine HCl versus placebo as adjunctive treatment for complex partial seizures. Epilepsia. 35:1994;54.
9. Sachedo R., Leroy R., Krauss G. et al. Safety and efficacy of bid and qid dosing with tiagabine HCl versus placebo as adjunctive treatment for partial seizures. Neurology. 45:1995;A202.
10. Uthman B. M., Rowan A. J., Ahman P. A., Leppik I. E. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Archives of Neurology. 55:1998;56-62.
11. Leppik I. E. Tiagabine: the safety landscape. Epilepsia. 36:1995;S10-S13.
12. Coenen A. M. L., Blezer E. H. M., Van Luijtelaar E. L. J. M. Effects of the GABA-uptake inhibitor tiagabine on electroencephalogram, spike-wave discharge and behaviour of rats. Epilepsy Research. 21:1995;89-94.
13. Coenen A. M. L., Dinkenburg W. H. I. M., Inoue M. et al. Genetic models of absence epilepsy, with emphasis on the WAG/Rij strain of rats. Epilepsy Research. 12:1992;75-86.
14. Vergnes M., Marescaux C., Micheletti G. et al. Enhancement of spike and wave discharges by GABA mimetic drugs in rats with spontaneous petit mal-like epilepsy. Neuroscience Letters. 44:1984;91-94.
15. Schapel G., Chadwick D. Tiagabine and non-convulsive status epilepticus. Seizure. 5:1996;153-156.
16. Eckhardt K. M., Steinhoff B. J. Non-convulsive status epilepticus in two patients receiving tiagabine treatment. Epilepsia. 39:1998;671-674.
17. Baulac M., Arzimanoglou A., Semah F., Cavalcanti D. Therapeutic options provided by new antiepileptic drugs. Revue Neurologique. 155:1997;21-33.
18. Cascino G. D. Non-convulsive status epilepticus in adults and children. Epilepsia. 34:1993;S21-S28.
19. Solomon G. E., Labar D. Hypothesis that tiagabine-induced NCSE is associated with GABA-ergic hyperfunction, with GABA(B) receptors playing a critical role, is supported by a case of generalized NCSE induced by baclofen. Epilepsia. 39:1998;1383.
20. Peeters B. W. M. M., van Rijn C. M., Vossen J. M. H. et al. Effects of GABA-ergic agents on spontaneous non-convulsive epilepsy, EEG and behaviour in the WAG/Rij inbred strain of rats. Life Science. 45:1989;1171-1176.
21. Maresaux C., Vernges M., Depaulis A. Genetic absence epilepsy in rats from Strasbourg - a review. Journal of Neural Transmission. 35 (Suppl.):1992;179-188.
22. Richards D. A., Lemos T., Whitton P. S. Extracellular GABA in the ventrolateral thalamus of rats exhibiting sponatneous absence epilepsy: a microdialysis study. Journal of Neurochemistry. 65:1995;1674-1680.
23. Hosford D. A., Wang Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrine, tiagabine, gabapentin and topiramate against human absence seizures. Epilepsia. 38:1997;408-414.
24. Futatsugi Y., Riviello J. J. Mechanisms of generalized absence epilepsy. Brain and Development. 20:1998;75-79.
25. Danober L., Deransart C., Depaulis A., Vergnes M., Marescaux C. Pathophysiological mechanisms of genetic absence epilepsy in the rat. Progress in Neurobiology. 55:1998;27-57.
26. Banerjee P. K., Tillakaratne N. J., Brailowsky S., Olsen R. W., Tobin A. J., Snead O. C. 3rd Alterations in GABA a receptor alpha 1 and alpha 4 subunit mRNA levels in thalamic relay nuclei following absence-like seizures in rats. Experimental Neurology. 154:1998;213-223.